Clinical Trial

A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 27, 2026 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to study the effect of sacituzumab govitecan-hziy in adult patients with advanced thymoma and thymic carcinoma after progressing on at least one prior line of therapy. The main question it aims to answer is: • What is the overall response rate (ORR) in patients with advanced thymoma and thymic carcinoma? Participants will: * receive a fixed dose of 10 mg/kg given intravenously, once weekly on Days 1 and 8 of continuous 21-day treatment cycles until disease progression or unacceptable toxicity * have regular blood tests, scans, and examinations to monitor their health. * have blood and a biopsy of their tumor for research purposes.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-01-31; most recent amendment 2026-01-23.
Status change: Not Yet Recruiting → Recruiting 2024-04-14
Trial Details
NCT Number NCT06248515
Lead Sponsor Georgetown University
Collaborators: Gilead Sciences
Conditions Thymoma, Thymic Carcinoma
Enrollment 18 participants
Start Date 2024-04-25
Primary Completion 2026-04 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-27